Moderna's stock fell sharply in premarket trading, sliding over 6% to $54.39 after the biotech giant released its second-quarter earnings report. Despite a slight uptick in revenue, surprises lurked beneath the surface, including a setback in its norovirus vaccine trial that sent investors reeling.

Revenue Edges Up Amid Cost Efficiency

The company reported $145 million in revenue for Q2, a modest increase from $142 million a year earlier. The U.S. market accounted for $87 million, with international sales contributing $58 million. Gains in the UK and partnership revenues helped offset declining COVID vaccine sales elsewhere. Impressively, Moderna slashed its cost of sales by 22% to $93 million, benefiting from improved manufacturing efficiency. This figure included $41 million in inventory write-downs and $23 million tied to unused manufacturing capacity. Research expenses also dropped 7% to $651 million after several development programs wrapped up.

Administrative and selling expenses followed suit, decreasing 6% to $216 million as the company imposed tighter spending controls. All told, Moderna narrowed its net loss to $782 million compared to $825 million in the same quarter last year. Loss per share improved to $1.97 from $2.13.

Adjusting Spending and Cash Flow Outlooks

Looking ahead, Moderna sticks to its 2026 revenue growth target of up to 10%, expecting roughly equal contributions from domestic and international markets. The company anticipates that 55% of its second-half revenue will come in Q3. However, it trimmed its cost of sales forecast from $1.8 billion to $1.7 billion and slashed research spending expectations by $100 million to $2.9 billion. Selling and administrative expenses are expected to hover near $1 billion.

Cash reserves fell from $7.5 billion in March to $6.9 billion by the end of June. This included a payment of $950 million related to a July litigation settlement. Moderna now projects year-end cash holdings in the range of $4.7 billion to $5.2 billion.

Mixed Results in Vaccine Pipeline

While Moderna scored regulatory nods and expanded commercial deals across Europe, Asia, and Latin America, not all news was positive. The company's norovirus vaccine missed its interim success target during a Phase 3 trial, dampening enthusiasm. Meanwhile, the FDA's decisions regarding Moderna’s seasonal flu vaccine candidates are expected on August 5, adding another key milestone to watch.

This material is for informational purposes only and does not constitute financial advice.